Therapeutic Antibodies: Bench to Market

Webinar Series of the Chinese Antibody Society

Upcoming Webinar

Register today to reserve your seat

EXCLUSIVE FOR MEMBERS

The current predominant therapeutic paradigm is based on maximizing drug-receptor occupancy to achieve clinical benefit. This strategy, however, generally requires excessive drug concentrations to ensure sufficient occupancy and efficacy, often contributing to adverse side effects. The proteolysis targeting chimeras (PROTACs) method uses bi-functional molecules to recruit ubiquitin E3 ligases to a specific protein target of interest, catalytically inducing its ubiquitination and degradation, therefore providing efficacy that is not limited by equilibrium occupancy. In addition, PROTACs also allow targeting non-enzymatic scaffolding function and potentially long-acting effect. As the number of E3 ligases amenable to recruitment continues to grow, PROTAC induced-protein degradation represents a new pharmacological strategy for highly efficient chemical protein knockdown with utility both as a chemical biology tool and also potentially as a clinically useful therapeutic modality.


Sign in to Register

Recent Webinars

Sign in to view recordings

Practical purification strategies for bispecific antibodies

09/25/2021

Dr Zhang Wei

Bispecific antibodies (bsAbs) represent a highly promising class of biotherapeutic modality, and its enormous therapeutic potential has led to the development of over 50 different formats of recombinant bsAbs reported so far. Although U.S. Food and Drug Administration (FDA) has approved only three bsAbs as of August 2021, there are …

The Role of Analytical Methods in Biologics CMC Development – A Lifecyle Perspective

08/28/2021

Dr. Jun Ouyang

Similar to what Confucius wrote over two thousand years ago: “if a craftsman wants to do good work, he must first sharpen his tools”, advanced and appropriate analytical methods are essential for any CMC programs to be successfully developed and progress from early to late stages. As we all know, …

Frontiers in targeting co-stimulation TNFRSF for cancer immunotherapy

07/24/2021

Jieyi Wang, PhD

Co-stimulation signalings in a variety types of immune cells modulate immune responses physiologically and in certain diseases. Tumor necrosis factor receptor superfamily (TNFRSF) members such as CD40, OX40 and CD137/4-1BB express on dendritic cells and/or lymphocytes, and they regulate antigen presentation and adaptive immune activities. TNFR agonistic antibodies have been …

New Immune Checkpoints: From Discoveries to Clinical Trials

06/26/2021

Prof. Dr. Xingxing Zang

The discovery of immune checkpoint pathways and the subsequent development of therapeutics that target these pathways have marked a revolution in the treatment of cancer and immunological diseases. FDA approved immune checkpoint inhibitors against CTLA-4, PD-1, and PD-L1 have seen significant clinical success for cancer therapy. Currently, the biggest challenge …

This web app is a Python Django project independently coded (frontend+backend+deployment on AWS) by Xin Yu (Github, LinkedIn) in her volunteer capacity at the Chinese Antibody Society. Contents are maintained by CAS IT team. If you're interested in participating in the future development of this web app, please submit a volunteer application and request an interview with the IT team. We require a minimum of 2 years experience as a Django developer. © Chinese Antibody Society 2021. All Rights Reserved. Legal Disclaimer
Icon